Inspiratory Muscle Training in Nemaline Myopathy (NEMTRAIN)

Inspiratory Muscle Training in Patients With Nemaline Myopathy

Nemaline myopathy is a rare congenital myopathy. Respiratory failure is the main cause of death in these patients. The primary objective of this study is to determine the effect of a 8-week inspiratory muscle training program on respiratory muscle function in nemaline myopathy patients. The secondary objective is to determine respiratory muscle function in nemaline myopathy patients and its correlation with clinical severity and general neuromuscular function. The nemaline myopathy patients will be included in the first phase for a clinical characterization. From this phase patients will be selected for the second phase, which is a controlled before-after trial of inspiratory muscle training. The primary outcome is the change in maximal inspiratory pressure (MIP) after active inspiratory muscle training

Study Overview

• Status: Completed
• Conditions: Inspiratory Muscle Training; Nemaline Myopathy
• Intervention / Treatment: Device: Threshold IMT, Philips Respironics, Murrysville, PA, USA

Detailed Description

Rationale: Nemaline myopathy is a group of congenital, hereditary neuromuscular disorders with variable symptoms such as muscle weakness, swallowing dysfunction, and dysarthria. Respiratory failure is the main cause of death in nemaline myopathy and occurs even in ambulant patients who otherwise appear to be only mildly affected; respiratory muscle weakness may even be the presenting feature. Inspiratory muscle training has shown to increase inspiratory muscle strength in patients with other neuromuscular disorders. It is hypothesized that inspiratory muscle training improves respiratory muscle function in nemaline myopathy patients with respiratory muscle weakness.

Objective: The primary objective is to determine the effect of a 8-week inspiratory muscle training program on respiratory muscle function in nemaline myopathy patients. The secondary objective is to determine respiratory muscle function in nemaline myopathy patients and its correlation with clinical severity and general neuromuscular function.

Study design: The study consist of two phases. Phase 1: A screening phase with an open design from which patients will be selected for the second phase. Phase 2: A controlled before-after trial of inspiratory muscle training. The 2 conditions tested are sham IMT and active IMT.

Study population: Nemaline myopathy patients from the local neuromuscular database will be recruited. Furthermore, other centres in the Netherlands will be contacted to expand the database of nemaline myopathy patients. Phase 2 requires 23 patients.

Intervention: Active IMT consists of 15 minutes of IMT, twice a day, 5 days per week for 8 weeks, at a training workload of 30% of MIP using a resistive inspiratory muscle training device. Sham IMT consists of similar training regime using a resistive inspiratory muscle training device where the resistance has been removed.

Main study parameters/endpoints: The primary outcome parameter is the change in maximal inspiratory pressure (MIP) after active inspiratory muscle training.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The intervention of inspiratory muscle training is not associated with any risks, but can be challenging in patients with respiratory muscle weakness to perform. There will be three visits to the hospital in 16 weeks. The first visit has a maximal duration of 6 hours (including breaks) and the other two visits 1.5 hour. During these visits several tests and physical examinations will be performed. Some of the tests may cause some physical discomfort, but none of them carry any risk. Patients may benefit from participating in this study by developing improved respiratory muscle function as a result of the inspiratory muscle training.

• Study Type: Interventional
• Enrollment (Actual): 42
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Nijmegen, Netherlands
    • Radboud university medical center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 years to 78 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• genetically-confirmed nemaline myopathy (mutations in one of the genes causing nemaline myopathy: TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFL2, KLHL40, KHLH41, LMOD3, MYPN, RYR1)
• informed consent from participant or legal representative
• age-range: between the age of 6-80 years

Exclusion Criteria:

• history of another condition that affects respiratory muscle strength or function (e.g. COPD)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Sham inspiratory muscle training; Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance. The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks.	Device: Threshold IMT, Philips Respironics, Murrysville, PA, USA; Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
Active Comparator: Active inspiratory muscle training; Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.	Device: Threshold IMT, Philips Respironics, Murrysville, PA, USA; Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of maximal inspiratory pressure (cmH2O)	Obtained with handheld device	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of diaphragm thickness (mm)	Obtained with ultrasound	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of diaphragm thickening (ratio)	Obtained with ultrasound	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of diaphragm excursion (cm)	Obtained with ultrasound	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of peak cough flow (L/s)	Obtained with handheld spirometry	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of forced vital capacity (% predicted)	Obtained with handheld spirometry	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of forced expiratory volume in the first second (% predicted)	Obtained with handheld spirometry	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of peak expiratory flow (L/s)	Obtained with handheld spirometry	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of (Slow) vital capacity (% predicted)	Obtained with handheld spirometry in sit and supine	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of sniff nasal inspiratory pressure (cmH2O)	Obtained with handheld device	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of maximal expiratory pressure (cmH2O)	Obtained with handheld device	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of twitch mouth pressure (cmH2O)	Measured after bilateral phrenic nerve stimulation	Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Maximal voluntary contraction (N)	Handgrip ergonometer	Baseline
Rate of muscle relaxation (N/s)	Measured by transcranial magnetic stimulation	Baseline
Motor Function Measure test	The items of the MFM are classified in 3 domains: D1: Standing and transfers (13 items, sub score range 0-39) D2: Axial and proximal motor function (12 items, sub score range 0-36) D3: Distal motor function (7 items, sub score range 0-21) Each item is scored on a 0-3 scale. Each sub score will be calculated as the percentage of total possible score achieved. Higher scores indicate a better outcome. The range of the total score is 0-96, again recalculated as the percentage of total possible score achieved.	Baseline
6-minute walk test	This test assesses distance walked over 6 minutes as a submaximal test of aerobic capacity/endurance. The outcome is compared to the reference values.	Baseline
Falls	The occurence of falls will be investigated retrospectively and prospectively during a 100-day period by questions composed by the investigators.	100-day period from baseline on
Mini-BESTest: Balance Evaluation Systems Test (Balance test for adults)	This test consists of several domains of balance and consequently of several sub scores: Anticipatory sub score 0-6 Reactive postural control 0-6 Sensory orientation sub score 0-6 Dynamic gait sub score 0-10 The sub scores are added up to a total score with a range of 0-28. Higher values represent a better outcome.	Baseline
Pediatric Balance Scale (Balance test for children)	This test consists of 14 item. The participant can score 0-4 on each item, with a maximum score of 56. Higher values represent a better outcome.	Baseline
The RAND 36-Item Health Survey	This questionnaire addresses eight concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Scoring the RAND 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key. All items are scored so that a high score defines a more favourable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered.	Baseline
Measurement model for the pediatric quality of life inventory: PedsQL	This questionnaire consists of 8 items on physical functioning, 5 items on emotional functioning, 5 items on social functioning, and 5 items on school functioning. Each item is scored on a 0-4 scale. The items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate a better outcome. To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. The Physical Health Summary Score is the same as the Physical Functioning Scale Score. To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.	Baseline

Collaborators and Investigators

• Sponsor: Radboud University Medical Center
• Investigators: Study Director: Baziel van Engelen, Prof. PhD, Promotor

Study record dates

Study Major Dates

• Study Start (Actual): October 10, 2018
• Primary Completion (Actual): March 25, 2021
• Study Completion (Actual): March 25, 2021

Study Registration Dates

• First Submitted: October 15, 2018
• First Submitted That Met QC Criteria: November 1, 2018
• First Posted (Actual): November 2, 2018

Study Record Updates

• Last Update Posted (Actual): July 7, 2021
• Last Update Submitted That Met QC Criteria: July 4, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Musculoskeletal Diseases; Neuromuscular Diseases; Myopathies, Structural, Congenital; Respiratory Aspiration; Muscular Diseases; Myopathies, Nemaline
• Other Study ID Numbers: NL65214.091.18

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No